Xoma reports Q2 EPS (33c), consensus (38c) » 17:4908/0608/06/20
Reports Q2 revenue $444K,…
Reports Q2 revenue $444K, consensus $2.27M. "With a healthy cash position, a low-cost infrastructure, and a strict discipline on capital deployment, XOMA remains in a strong position to continue executing on our royalty-aggregator strategy to create near- and long-term value for shareholders. We were pleased to expand our Board of Directors with the appointment of Natasha Hernday, Senior Vice President, Corporate Development at Seattle Genetics, who brings significant expertise in sourcing and executing licensing deals, acquisitions, and partnerships that are complementary to our business model," stated Jim Neal, Chief Executive Officer. "We recognize COVID-19 continues to impact clinical activities broadly across the industry, and while these challenges may affect the timing of potential milestone payments due to XOMA, they also could create opportunities for us to acquire interesting milestone and royalty assets. "We commend our partners for their continued focus on advancing their therapeutic candidates in the face of COVID-19-related challenges. For example, Ology Bioservices was awarded a contract from the Department of Defense to further its anti-botulinum toxin program," Mr. Neal added. "Recently, Sesen Bio announced it signed an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum(TM), a locally administered fusion protein being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC), in Greater China."
Merus reports Q2 EPS (54c), consensus (61c) » 17:2708/0608/06/20
Reports Q2 revenue…
Reports Q2 revenue $6.06M, consensus $7.51M. "We are pleased to report several updates and progress with our business this quarter," said Bill Lundberg, president, CEO and Principal Financial Officer of Merus. "On the clinical side, Dr. Andrew Joe has been appointed Chief Medical Officer, bringing over 20 years of clinical experience developing cancer therapies, including molecularly-targeted and tumor-agnostic therapies, to the Merus team. On the business side, we have prudently focused our projected spend and anticipate our cash runway will fund our operations into the second half of 2022, putting us in a strong financial position. We look forward to providing a substantive clinical update on zenocutuzumab (Zeno) for neuregulin 1 (NRG1) fusion cancers by year end."
Iveric bio files to sell 8.65M shares of common stock for holders 17:2708/0608/06/20
Five Prime reports Q2 EPS (48c), consensus (61c) » 16:3608/0608/06/20
"We remain on track…
Kura Oncology files $300M mixed securities shelf 16:3508/0608/06/20
Kura Oncology reports Q EPS (40c), consensus (42c) » 16:2608/0608/06/20
Cash, cash equivalents…
Cash, cash equivalents and short-term investments totaled $338.9M as of June 30, including net proceeds of approximately $134.9M from a public offering completed in May, compared with $236.9M as of December 31, 2019. "Last quarter we implemented a number of strategic measures to focus on our two major development pillars: tipifarnib in HRAS-dependent head and neck squamous cell carcinoma (HNSCC) and KO-539 in acute myeloid leukemia (AML)," said Troy Wilson, CEO of Kura Oncology. "We believe tipifarnib and KO-539 provide opportunities to address large proportions of head and neck cancers and acute leukemias, respectively. Now, following a successful public offering this past quarter, we are well-positioned to advance each of these programs toward important upcoming catalysts."
Y-mAbs Therapeutics reports Q2 EPS ($1.01), consensus (68c) » 16:0508/0608/06/20
The Company had…
Y-mAbs Therapeutics completes Omburtamab BLA submission » 09:0108/0608/06/20
Sierra Oncology names Kevin Norrett as Chief Business Officer » 08:2208/0608/06/20
Sierra Oncology announced…
Sierra Oncology announced the appointments of Kevin Norrett as Chief Business Officer and William Turner as Chief Regulatory and Technical Operations Officer. Most recently, Kevin was Chief Commercial Officer at Angion Biomedica, a clinical stage company with a focus in acute organ injury and fibrosis. Turner was Senior Vice President of Technical Operations and Regulatory Science at Aimmune Therapeutics for several years.
Sierra Oncology reports Q2 EPS ($1.58), consensus ($1.63) » 08:0508/0608/06/20